Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investigational drug voclosporin for the treatment of lupus nephritis, other proteinuric diseases and dry eye syndrome.
The shares are being sold at a public offering price of $15 per share. The gross offering proceeds to the company from this Offering are expected to be approximately $200 million The offering is expected to close on or about July 27, 2020, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds of the offering for pre-commercialization and launch activities, research and development, as well as working capital and general corporate purposes.